Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Systemic Sclerosis Therapy
Research reports from Fred Hutchinson Cancer Research Center provide new insights into systemic sclerosis therapy
August 27th, 2007
Investigators publish new data in the report "High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study." According to recent research from the United States, "More effective therapeutic strategies are required for patients with poor-prognosis systemic sclerosis (SSc). A phase 2 single-arm study of high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected hematopoietic cell transplantation (HCT) was conducted in 34 patients with diffuse cutaneous SSc." "HDIT included total body irradiation (800 cGy) with lung shielding, cyclophosphamide (120...
Source: Clinical Trials Week (2007-08-27)
|
